Comparing GLP-1 Medications: Ozempic, Wegovy, Mounjaro, Zepbound
A side-by-side look at the most commonly prescribed GLP-1 and dual GIP/GLP-1 options in the US market.
Patients often arrive at their first weight-management appointment already familiar with the brand names—Ozempic, Wegovy, Mounjaro, Zepbound—but less clear on how these medications actually differ. Understanding the distinctions helps you have a more productive conversation with your prescriber and set realistic expectations. This guide compares the leading GLP-1 and GIP/GLP-1 medications available in the U.S. market.
Semaglutide: Ozempic and Wegovy
Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk. It is sold under two brand names in the United States. Ozempic is FDA-approved for type 2 diabetes and, more recently, for reducing cardiovascular risk in adults with type 2 diabetes and established heart disease. Wegovy is FDA-approved for chronic weight management in adults and adolescents meeting BMI criteria, and for cardiovascular risk reduction in adults with obesity and heart disease.
Both products contain the same active ingredient but come in different dose strengths and titration schedules tailored to their approved uses. Wegovy titrates up to a 2.4 mg weekly dose for weight management, while Ozempic tops out at 2.0 mg for diabetes management. In pivotal trials, average weight loss with semaglutide at the highest doses ranged from roughly 12 to 15 percent of body weight over 68 weeks in adults with obesity without diabetes.
Tirzepatide: Mounjaro and Zepbound
Tirzepatide, manufactured by Eli Lilly, acts on two hormone receptors—GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism appears to produce stronger effects on appetite, insulin sensitivity, and fat metabolism than GLP-1 alone in many patients. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management and, more recently, for moderate to severe obstructive sleep apnea in adults with obesity.
In head-to-head and cross-trial comparisons, tirzepatide has demonstrated somewhat greater average weight loss than semaglutide, with pivotal trial data showing average reductions of roughly 15 to 21 percent of body weight at the highest doses over 72 weeks in adults with obesity.
Liraglutide: Victoza and Saxenda
Liraglutide is an older GLP-1 medication administered by daily injection rather than weekly. Victoza is approved for type 2 diabetes; Saxenda is approved for chronic weight management. Weight loss with liraglutide is typically more modest—around 5 to 8 percent of body weight on average—and the daily injection schedule is less convenient. It remains an option for patients who cannot access weekly formulations or who tolerate daily dosing better.
Dulaglutide: Trulicity
Dulaglutide is a weekly GLP-1 injection approved for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes. It is not FDA-approved for weight loss, though modest weight reduction is often observed as a secondary effect. It is not typically prescribed for weight management as a primary goal.
Oral semaglutide: Rybelsus
Rybelsus is an oral formulation of semaglutide approved for type 2 diabetes. Weight loss is generally less pronounced than with the injectable versions, and dosing requires taking the tablet on an empty stomach with a small amount of water and waiting before eating. An oral formulation specifically approved for weight management is under development.
Side effect profiles
All GLP-1 and GIP/GLP-1 medications share a similar side effect profile, dominated by gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, and reflux. These symptoms are most common during dose escalation and generally improve over time. Rarer but more serious risks include pancreatitis, gallbladder problems, and, based on rodent studies, a boxed warning regarding medullary thyroid carcinoma. Individual tolerability varies, and switching between agents is sometimes appropriate if side effects on one drug are intolerable.
How clinicians choose between them
The right medication depends on several factors:
- Approved indication: Diabetes, weight management, cardiovascular risk, or sleep apnea.
- Insurance coverage: Formularies often favor one brand over another.
- Efficacy needs: Patients seeking greater weight loss may lean toward tirzepatide.
- Tolerability: Some patients feel better on one molecule than another.
- Dosing schedule: Weekly injections are usually preferred over daily.
- Access and supply: Ongoing manufacturing pressure can affect availability.
Off-label prescribing and combinations
Some clinicians prescribe Ozempic or Mounjaro off-label for weight loss in patients whose insurance covers the diabetes brand but not the weight-management brand. Combining GLP-1 medications with other weight-loss drugs is not standard practice and should be discussed carefully with a qualified provider. Do not layer medications on your own.
What patients should ask
When comparing options, ask your clinician which medication is most appropriate for your medical history, whether coverage differs between the diabetes and weight-management brands under your plan, what side effects to expect, and what the plan is if you cannot tolerate the first choice. A thoughtful comparison up front prevents wasted months on a medication that is a poor fit for your situation.
All of these medications share more similarities than differences, but the nuances—dosing, indication, coverage, tolerability, and expected weight loss—matter for finding the right fit.
GLP-1 weight loss FAQs
Common questions related to comparing glp-1 medications: ozempic, wegovy, mounjaro, zepbound and GLP-1 therapy in the USA.
What are GLP-1 medications and how do they help with weight loss?
GLP-1 receptor agonists mimic a natural gut hormone that signals fullness to the brain and slows how quickly the stomach empties. In the USA, drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management and typically produce 10–20% body weight loss over a year when combined with lifestyle changes.Who qualifies for a GLP-1 weight loss prescription in the USA?
Adults with a BMI of 30 or higher, or 27+ with a weight-related condition such as type 2 diabetes, hypertension, or sleep apnea, generally qualify. A licensed US healthcare provider must evaluate your medical history, current medications, and contraindications before prescribing.How much does GLP-1 weight loss treatment cost in the United States?
Without insurance, brand-name GLP-1 medications typically cost $900–$1,500 per month. Manufacturer savings cards can lower costs for eligible commercially insured patients. Coverage varies widely: many plans require prior authorization, and Medicare currently has limited coverage for weight-loss indications.Does insurance cover GLP-1 drugs for weight loss?
Coverage depends on your plan. Many commercial insurers cover GLP-1s for type 2 diabetes but restrict or exclude coverage for obesity. When covered for weight loss, prior authorization usually requires documented BMI, prior weight-loss attempts, and comorbidities. Appeals are common and often successful with provider support.What are the most common side effects?
Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are most common, especially during dose escalation. Serious but rare risks include pancreatitis and gallbladder disease. People with a personal or family history of medullary thyroid carcinoma or MEN2 should not use GLP-1s.How long do I need to stay on a GLP-1 medication?
Obesity is treated as a chronic condition. Clinical evidence shows that most patients regain weight after stopping GLP-1s, so long-term use — often years — is typical. Your provider may adjust the dose over time and combine treatment with nutrition, exercise, and behavioral support.Is it safe to get GLP-1 prescriptions through telehealth?
Reputable telehealth platforms with licensed US clinicians, thorough medical reviews, and ongoing follow-up can be safe and convenient. Be cautious of services that prescribe without evaluating your history, use unregulated compounded products, or lack proper pharmacy oversight.Can I lose weight on a GLP-1 without changing my diet or exercise?
You may lose some weight, but outcomes are significantly better — and more sustainable — when medication is paired with adequate protein intake, resistance training, sleep, and stress management. Lifestyle habits also help protect muscle mass and metabolic health during weight loss.